Nektar Therapeutics (NKTR)

Nektar Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	39.27	15.12	44.25	35.28	88.23	25.22
Short-Term Investments	645.07	230.64	210.97	268.34	416.75	708.74
Cash & Short-Term Investments	684.34	245.75	255.23	303.62	504.98	733.96
Cash Growth	289.05%	-3.71%	-15.94%	-39.88%	-31.20%	-30.88%
Accounts Receivable	-	-	-	1.21	5.98	22.49
Other Receivables	4.76	1.78	1.61	1.05	2.42	1.4
Receivables	4.76	1.78	1.61	2.25	8.4	23.89
Inventory	-	-	-	16.1	19.2	15.8
Prepaid Expenses	2.16	2.2	2.51	4.41	5.99	-
Other Current Assets	48.15	16.54	1.95	4.33	7.4	21.93
Total Current Assets	739.4	266.27	261.29	330.7	545.97	795.58
Property, Plant & Equipment	-	5	11.82	36.86	85.89	177.54
Long-Term Investments	339.06	3.49	26.09	25.83	-	64.83
Goodwill	-	-	-	-	76.5	76.5
Other Long-Term Assets	16.67	5.65	4.65	4.64	2.25	2.74
Total Assets	1,095	280.41	303.85	398.03	710.6	1,117

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	24.89	10.77	11.56	9.85	12.98	9.75
Accrued Expenses	19.88	19.64	27.21	19.14	28.85	58.01
Current Portion of Leases	22.71	20.5	19.87	19.26	18.67	17.44
Other Current Liabilities	3.51	2.63	2.77	3.02	7.71	-
Total Current Liabilities	70.99	53.54	61.4	51.27	68.2	85.2
Long-Term Debt	57.38	63.16	91.78	112.63	155.38	195.43
Long-Term Leases	55.85	65.26	82.7	98.52	112.83	125.74
Other Long-Term Liabilities	7.8	8.63	7.24	4.64	7.55	31.32
Total Liabilities	192.01	190.57	243.11	267.05	343.96	437.68

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0	0	0	0.02	0.02	0.02
Additional Paid-In Capital	4,751	3,850	3,660	3,608	3,575	3,517
Retained Earnings	-3,846	-3,760	-3,596	-3,477	-3,201	-2,833
Treasury Stock	-	-	-3	-	-	-
Comprehensive Income & Other	-1.76	0.02	0.06	0.08	-6.91	-4.16
Shareholders' Equity	903.12	89.83	60.74	130.99	366.64	679.51
Total Liabilities & Equity	1,095	280.41	303.85	398.03	710.6	1,117

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	135.93	148.91	194.34	230.4	286.87	338.6
Net Cash (Debt)	548.41	96.84	74.76	99.04	218.1	460.18
Net Cash Growth	-	29.55%	-24.52%	-54.59%	-52.61%	-45.73%
Net Cash Per Share	22.57	5.74	5.45	7.82	17.48	37.66
Filing Date Shares Outstanding	34.14	28.69	12.41	12.24	12.62	12.42
Total Common Shares Outstanding	34.13	20.38	12.39	12.76	12.57	12.36
Working Capital	668.42	212.73	199.89	279.43	477.76	710.38
Book Value Per Share	26.46	4.41	4.90	10.27	29.17	54.96
Tangible Book Value	903.12	89.83	60.74	130.99	290.14	603.01
Tangible Book Value Per Share	26.46	4.41	4.90	10.27	23.08	48.77
Buildings	-	-	-	43.18	74.89	97.39
Machinery	-	-	-	61.83	79.76	104
Construction In Progress	-	-	-	0.74	2.53	7.16

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 8, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 27, 2026

Data Sources Report a data error